Neuroprotective therapy

Seminars in Neurology

Volumn 18, Issue 4, 1998, Pages 485-492

  Hickenbottom, Susan L ^a   Grotta, James ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Neuroprotection; Stroke; Therapy

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; APTIGANEL; CALCIUM CHANNEL BLOCKING AGENT; CITICOLINE; CLOMETHIAZOLE; FIBRINOLYTIC AGENT; FOSPHENYTOIN SODIUM; GANGLIOSIDE GM1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LUBELUZOLE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NIMODIPINE; PIRACETAM; PLACEBO; REPINOTAN; SODIUM CHANNEL BLOCKING AGENT; TIRILAZAD;

BRAIN ISCHEMIA; CALCIUM TRANSPORT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 0032434654     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040901     Document Type: Review

References (46)

1. Reith J, Jorgensen HS, Pedersen PM, et al. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet 1996;347:422-425
2. Marion DW, Penrod LE, Kelsey SF, et al. Treatment of traumatic brain injury with moderated hypothermia. N Engl J Med 1997;336:540-546
3. Ginsberg MD. Neuroprotection in brain ischemia: an update (part I). Neuroscientist 1995;1:95-103
4. Hossman K: Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994; 36:557-565
5. DeGraba TJ, Ostrow PT, Strong RA, et al. The temporal relation of calcium-calmodulin binding and neuronal damage after global ischemia. Stroke 1992;23:876-882
6. Aronowski J, Waxham N, Grotta J. Neuronal protection and preservation of calcium/calmodulin-dependent protein kinase II and protein kinase C by dextrorphan treatment in global ischemia. J Cerebr Flow Metab 1993;15:550-557
7. Kohno K, Hoehn-Berlage M, Mies G, Bach T, Hossmann KA. Relationship between diffusion weighted MR images, cerebral blood flow, and energy state in experimental brain infarction. Mag Res Imaging 1995;13:73-80
8. Jarvis RA, Triggle DJ. Drugs acting on calcium channels. In Hurwitz L, Partridge LD, Leach JK, eds. Calcium Channels: Their Properties, Functions, Regulation, and Clinical Relevance. Boca Raton, FL: CRC Press, 1991:195-249
9. van den Kerchoff W, Drewes LR. Transfer of Ca-antagonists nifedipine and nimodipine across the blood brain barrier and their regional distribution in vivo [abstract]. J Cereb Blood Flow Metab 1985;5(Suppl 1):459-460
10. Grotta JC. Clinical aspects of the use of calcium antagonists in cerebrovascular disease. Clin Neuropharmacol 1991;14:373-390
11. Gelmers HJ, Gorter K, de Weerdt CJ, Wiezer HJA. A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med 1988;318:203-207
12. Wahlgren N, MacMahon D, De Keyser J, et al. for the INWEST Study Group: Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994;4:204-210
13. Mohr J, Orgogozo J, Harrison M, et al. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994;4:197-203
14. de Keyser J. Opportunities for neuroprotection. Acute Stroke Manag. 1997;2:11-14
15. Rosenbaum D, Zambramski J, Frey J, et al. Early treatment of ischemic stroke with a calcium antagonist. Stroke 1991;22:437-441
16. Lataste X, Maurer W, Whitehead J, and the ASCLEPIOS Study Group. Application of sequential methods to clinical trial in stroke: the ASCLEPIOS study. Presented at the 2nd World Congress of Stroke, 1992, p. S16
17. Limburg M, Hijdra A. Flunarizine in acute ischemic stroke: a pilot study. Eur Neurol 1990;30:121-122
18. Grotta J, Clark W, Coull B, et al. Safety and tolerability of the glutamate antagonist CGS19755 (Selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. Stroke 1995;22:437-441
19. Davis SM, Albers GW, Diener HC, Lees KR, Norris J (ASSIST Steering Committee). Termination of acute stroke studies involving Selfotei treatment. Lancet 1997;349:32
20. Albers GW, Atkinson RP, Kelley RE, et al. Safety, tolerability, and pharmacokinetics of the N-methyl-d-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 1995;26:254-258
21. Fisher M for CNS1102-003 Investigators. Cerestat (CNS 1102), a noncompetitive NMDA antagonist, in ischemic stroke patients: dose-escalating safety study. Cerebrovasc Dis 1994;4:245
22. Turrini R. A pivotal safety and efficacy trial of Cerestat (Aptiganel HC1/CNS) in acute ischemic stroke patients. Stroke 1996;27:173
23. Albers GW, Clark WM, Atkinson RP, et al. Dose escalation study of the NMDA glycine site antagonist ACEA 1021 in acute ischemic stroke. Stroke 1997;28:233
24. Muir KW, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke 1995;26:1183-1188
25. Crumrine RC, Bergstrand K, Cooper AT, Ferison WL, Cooper BR. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke 1997;28:2230-2236
26. Diener HC, Hacke W, Hennerici M, et al. Lubeluzole in acute ischemic stroke: a double blind placebo controlled phase II trial. Stroke 1996;27:76-81
27. Grotta J for the US and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment for acute ischemic stroke. Stroke 1997;28:2338-2346
28. Diener HC, Kaste M, Hacke W, et al. for the LUB-INT-5 Lubeluzole Study Group: lubeluzole in acute ischemic stroke. Stroke 1997;28:271
29. Hantson L, Wessel T. Therapeutic benefits of lubeluzole in ischemic stroke. Stroke 1998;29:287
30. Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA. A randomized dose-response trial of citicholine in acute ischemic stroke patients. Neurology 1997;49:671-678
31. Clark WM, Williams BJ, Selzer KA, Zweifler RA, Sabounjian LA, for the Citicholine Study Group. Randomized trial of citicholine in acute ischemic stroke. Stroke 1998;29:287
32. Koroshetz WJ, Moskowitz MA. Emerging treatments for stroke in humans. Trends Pharmacol Sci 1996;17:227-233
33. The STIPAS Investigators. Safety study of tirilizad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 1994;25: 418-423
34. Peters GR, Hwang LJ, Musch B, Brosse DM, Orgogozo JM. Safety and efficacy of 6 mg/kg/day tirilizad mesylate in patients with acute ischemic stroke (TESS Study). Stroke 1996;27:195
35. RANTTAS Investigators. A randomized trial of tirilizad mesylate in patients with acute ischemic stroke. Stroke 1996;27:1453-1458
36. Enlimomab Acute Stroke Trial Study Group. The enlimomab acute stroke trial final results. Neurology 1997;48:A270
37. Lenzi GL, Grigoletto F, Gent M, et al. Early treatment of stroke with monosialoganglioside GM-1: efficacy and safety results of the Early Stroke Trial. Stroke 1994;25:1552-1558
38. Alter M for the SASS Investigators. Ganglioside GM-1 in acute ischemic stroke. The SASS trial. Stroke 1994;25:1141-1148
39. Wahlgren NG, for the Clomethiazole Acute Stroke Study collaborative group: The Clomethiazole Acute Stroke Study (CLASS): efficacy results in a subgroup of 545 patients with total anterior circulation syndrome. Stroke 1998;29:287
40. Squire IB, Lees KR, Pryse-Phillips W, Kertesz A, Bamford J. Efficacy and tolerability of lifarizine in acute ischemic stroke. Ann NY Acad Sci 1995;765:317-318
41. De Deyn PP, De Reuck J, Deberdt W, Vlietinck, Orgogozo J for Members of the Piracetam in Acute Stroke Study (PASS) Group. Treatment of acute ischemic stroke with piracetam. Stroke 1997;28:2347-2352
42. Clark WM, Coull BM, Karukin M, et al. Randomized trial of cervene, a kappa receptor-selective opioid antagonist, in acute ischemic stroke. J Stroke Cerebrovasc Dis 1996;6:35-40
43. Olinger CP, Adams HP, Brott TG, et al. High-dose intravenous naloxone for the treatment of acute ischemic stroke. Stroke 1990;21:721-725
44. The FIBLAST Safety Study Group. Clinical safety trial of intravenous basic fibroblast growth factor (bFGF, FIBLAST) in acute stroke. Stroke 1998;29:287
45. Grotta J, Aronowski J. DCLHb for focal ischemia and reperfusion. Cerebrovasc Dis 1996;6:189
46. Chiu D, Grotta J. Current clinical status of cytoprotection. In: Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B, eds. Primer on Cerebrovascular Diseases. San Diego: Academic Press 1997:731-737